NCT02528175View on ClinicalTrials.gov

Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2022

Conditions
Recurrent Rectal Cancer
Interventions
DEVICE

Magnetic resonance-guided focused ultrasound

Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.

RADIATION

Standard Radiation

30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).

DRUG

Chemotherapy

3.5 weeks concurrent with radiation therapy (institutional standard).

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

Sponsors

Collaborators (1)

Philips Medical Systems
All Listed Sponsors
collaborator

Philips Medical Systems

INDUSTRY

lead

William Chu, MD, MSc, FRCPC

OTHER